These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 137938)

  • 21. Binding of glycyrrhetinic acid to kidney mineralocorticoid and glucocorticoid receptors.
    Ulmann A; Menard J; Corvol P
    Endocrinology; 1975 Jul; 97(1):46-51. PubMed ID: 166832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extinction of mineralocorticoid effects in 19-norprogesterone derivatives: structure-activity relationships.
    Paris J; Botella J; Fournau P; Bonnet P; Thevenot R
    J Pharmacol Exp Ther; 1987 Oct; 243(1):288-91. PubMed ID: 2822901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood pressure changes following chronic administration to rats of 3beta,16beta-dihydroxy-5-androsten-17-one, 3beta,17beta-dihydroxy-5-androsten-16-one and 21-hydroxy-4-pregnene-3,20-dione-21-acetate.
    Ogihara T; Ichihara K; Yamamoto T; Kumahara Y; Kircher HW; Nugent CA
    Steroids; 1977 Jan; 29(1):17-20. PubMed ID: 138980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A case of apparent mineralocorticoid excess caused by type 2 11 beta- hydroxysteroid dehydrogenase deficiency].
    Morineau G; Pascoe L; Marc JM; Caillette A; Krozowski Z; Corvol P; Fiet J
    Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1111-5. PubMed ID: 9404418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mineralocorticoid receptor-like aldosterone-binding protein in cell culture.
    Lan NC; Matulich DT; Morris JA; Baxter JD
    Endocrinology; 1981 Dec; 109(6):1963-70. PubMed ID: 6273124
    [No Abstract]   [Full Text] [Related]  

  • 26. Mineralocorticoid resistance.
    Geller DS
    Clin Endocrinol (Oxf); 2005 May; 62(5):513-20. PubMed ID: 15853818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 19-Oxo-deoxycorticosterone binds to the renal mineralocorticoid receptor and produces sodium retention but not potassium excretion.
    Thomas CJ; Gomez-Sanchez CE; Marver D; Gomez-Sanchez EP
    Endocrinology; 1983 Aug; 113(2):517-22. PubMed ID: 6307643
    [No Abstract]   [Full Text] [Related]  

  • 28. Evidence for the secretion of an antimineralocorticoid in congenital adrenal hyperplasia.
    Kuhnle U; Land M; Ulick S
    J Clin Endocrinol Metab; 1986 May; 62(5):934-40. PubMed ID: 3007560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction of synthetic progestagens with renal mineralocorticoid receptors.
    Wambach G; Higgins JR; Kem DC; Kaufmann W
    Acta Endocrinol (Copenh); 1979 Nov; 92(3):560-7. PubMed ID: 574701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mineralocorticoid receptors in the rat lung.
    Krozowski Z; Funder JW
    Endocrinology; 1981 Dec; 109(6):1811-3. PubMed ID: 6273117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of deoxycorticosterone acetate and 16beta-hydroxy-dehydroepiandrosterone on blood pressure and plasma renin activity of rats.
    Ayachi S; Hall CE; Holland OB; Gomez-Sanchez C
    Proc Soc Exp Biol Med; 1976 Jun; 152(2):218-20. PubMed ID: 132667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mineralocorticoid receptors and 18-hydroxydeoxycorticosterone binding in the kidney of the spontaneously hypertensive rat.
    Feldman D
    Endocrinology; 1974 Apr; 94(4):1185-8. PubMed ID: 4818778
    [No Abstract]   [Full Text] [Related]  

  • 33. 19-Nor progesterone is a mineralocorticoid agonist.
    Funder JW; Adam WR
    Endocrinology; 1981 Jul; 109(1):313-5. PubMed ID: 6263590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Origin of urinary 16 beta-hydroxydehydroepiandrosterone in essential hypertension.
    Nowaczynski W; Messeril FH; Kuchel O; Guthrie GP; Genest J
    J Clin Endocrinol Metab; 1977 Apr; 44(4):629-38. PubMed ID: 139414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paradoxical nature of mineralocorticoid receptor antagonism by progestins.
    Agarwal MK; Paillard J
    Biochem Biophys Res Commun; 1979 Jul; 89(1):77-84. PubMed ID: 573122
    [No Abstract]   [Full Text] [Related]  

  • 36. [Determination and action mechanism of mineralocorticoids].
    Kumagai A; Nishikawa T
    Nihon Rinsho; 1981 Sep; 39(9):2993-8. PubMed ID: 6279930
    [No Abstract]   [Full Text] [Related]  

  • 37. The mineralocorticoid antagonist activity of an 11 beta,18-oxidopregnane.
    Ulick S; Marver D; Adam WR; Funder JW
    Endocrinology; 1979 May; 104(5):1352-6. PubMed ID: 436780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aldosterone binding to mineralocorticoid receptors of mononuclear leukocytes in diabetic subjects.
    Shimada T; Yasuda K; Mori A; Ni H; Mercado-Asis LB; Murase H; Miura K
    Acta Endocrinol (Copenh); 1993 Jun; 128(6):529-35. PubMed ID: 8393258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Studies on the mechanism of mineralocorticoid-induced hypertension: evidence for the presence of an in-situ mechanism in the arterial wall for a direct action of mineralocorticoids.
    Kornel L
    Clin Biochem; 1981 Oct; 14(5):282-93. PubMed ID: 7037229
    [No Abstract]   [Full Text] [Related]  

  • 40. Mineralocorticoid effector mechanism in human mononuclear leukocytes.
    Armanini D; Wehling M; Weber PC
    J Steroid Biochem; 1987; 27(4-6):967-70. PubMed ID: 2826915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.